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The major development of the past decade in the first-line treatment of recurrent 
and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the 
introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy 
(CT), followed by maintenance cetuximab (the “EXTREME” regimen). This regimen is 
supported by a phase 3 randomized trial and subsequent observational studies, and 
it confers well-documented survival benefits, with median survival ranging between 
approximately 10 and 14 months, overall response rates between 36 and 44%, and 
disease control rates of over 80%. Furthermore, as indicated by patient-reported out-
come measures, the addition of cetuximab to platinum-based CT leads to a significant 
reduction in pain and problems with social eating and speech. Conversely, until very 
recently, there has been a lack of evidence-based second-line treatment options, and 
the therapies that have been available have shown low response rates and poor survival 
outcomes. Presently, a promising new treatment option in R/M SCCHN has emerged: 
immune checkpoint inhibitors (ICIs), which have demonstrated favorable results in sec-
ond-line clinical trials. Nivolumab and pembrolizumab are the first two ICIs that were 
approved by the US Food and Drug Administration. We note that the trials that showed 
benefit with ICIs included not only patients who previously received ≥1 platinum-based 
regimens for R/M SCCHN but also patients who experienced recurrence within 6 months 
after combined modality therapy with a platinum agent for locally advanced disease. In 
this review, we outline the available clinical and observational evidence for the EXTREME 
Abbreviations: 5-FU, 5-fluorouracil; ADCC, antibody-dependent cell-mediated cytotoxicity; BSC, best supportive care; CT, 
chemotherapy; CTLA-4, cytotoxic T-lymphocyte antigen-4; ECOG PS, Eastern Cooperative Oncology Group performance 
status; EGFR, epidermal growth factor receptor; EXTREME, cetuximab plus cisplatin/carboplatin plus 5-fluorouracil followed 
by maintenance cetuximab; HPV, human papillomavirus; IC, investigator’s choice; ICI, immune checkpoint inhibitor; IgG, 
immunoglobulin G; LA, locally advanced; mAb, monoclonal antibody; NK, natural killer; ORR, overall response rate; OS, 
overall survival; PCE, paclitaxel, carboplatin, and cetuximab, followed by cetuximab maintenance until PD or toxicity; PD, 
progressive disease; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PFS, progression-free 
survival; PI3K, phosphoinositol-3-kinase; R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and 
neck; TPE and TPEx, cisplatin, docetaxel, cetuximab.
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regimen and the initial results from clinical trials for ICIs in patients with R/M SCCHN. We 
propose that these treatment options can be integrated into a new continuum of care 
paradigm, with first-line EXTREME regimen followed by second-line ICIs. A number of 
ongoing clinical trials are comparing regimens with ICIs, alone and in combination with 
other ICIs or CT, with the EXTREME regimen for first-line treatment of R/M SCCHN. As 
we eagerly await the results of these trials, the EXTREME regimen remains the standard 
of care for the first-line treatment of R/M SCCHN.
Keywords: cetuximab, squamous cell carcinoma of the head and neck, immune checkpoint inhibitor, eXTReMe, 
platinum-refractory, recurrent and/or metastatic, programmed cell death protein 1, programmed cell death 
ligand 1
iNTRODUCTiON
Head and neck cancer accounts for over 500,000 new cases and 
nearly 300,000 deaths annually worldwide as of 2012 (1, 2). 
Treatment options for patients with this disease vary according 
to the disease setting as well as other clinical characteristics. 
Patients with localized squamous cell carcinoma of the head and 
neck (SCCHN) (American Joint Committee on Cancer stages 
I-IVB) are treated with potentially curative therapy using ≥1 
treatment modalities [surgery, radiation therapy, chemotherapy 
(CT), and biologic therapy]. However, many patients develop 
recurrent disease; the recurrence rate in early-stage SCCHN is 
≈10–20% (3), whereas the recurrence rate in locally advanced 
(LA) SCCHN is ≈50% with a predominance of locoregional fail-
ure (4–6). Patients with recurrent or metastatic (R/M) SCCHN 
have a poor prognosis with median overall survival (OS) of 
under 1 year (7). This population includes patients whose dis-
ease recurred locally or who developed distant metastasis after 
initial treatment for localized disease and the rare patients with 
distant metastasis at first presentation. A small percentage of 
patients with localized recurrence can be treated with curative 
intent, but the vast majority receive palliative treatment with 
systemic therapy. In the first-line treatment of R/M SCCHN, 
combination therapy with cetuximab plus cisplatin/carboplatin 
plus 5-fluorouracil (5-FU) followed by maintenance cetuximab 
(the “EXTREME” regimen) has shown the best results so far in 
terms of overall response rate (ORR), progression-free survival 
(PFS), and OS (8, 9). A variation on this regimen allows for the 
substitution of 5-FU for a taxane (e.g., docetaxel or paclitaxel) 
(10, 11). In clinical practice, other combinations, such as a taxane 
or cisplatin plus cetuximab, are also sometimes used as first-line 
treatment for R/M SCCHN when patients are not fit enough for 
the EXTREME regimen, even though these are not evidence-
based approaches.
Patients who progress on—or are ineligible for—the 
EXTREME regimen and other cetuximab-based first-line treat-
ments have a dearth of efficacious therapeutic options. ORRs to 
commonly used therapies (including methotrexate, docetaxel, 
paclitaxel, and cetuximab as monotherapies) drop off to well 
under 20% and median survival in phase 3 trials has been repro-
ducibly reported at ≈5–6 months (7, 12–16). This grim outlook 
for second-line treatment is being reshaped by the introduction 
of immune checkpoint inhibitors (ICIs); results of recent trials 
will be reviewed here.
As more treatment options become available, it is reasonable 
to propose that the outcomes for patients with R/M SCCHN 
could be optimized with the appropriate succession of treatment 
regimens. Maximizing the number of therapy lines and optimiz-
ing the order in which therapies are administered has been one 
of the most powerful tools for delivering maximum benefit to 
patients (17, 18). Therefore, it is important to integrate as many 
lines of potentially efficacious therapy as possible into the treat-
ment paradigm to generate a maximally effective and tolerable 
multi-line continuum of care.
Here, we review the clinical data and propose an optimal 
sequence of systemic therapies to maximize the continuum of care 
in R/M SCCHN based on currently available evidence (Figure 1). 
Non-systemic therapies (radiation therapy, surgery) are outside 
the scope of this manuscript and will not be discussed in detail.
AvAiLABLe TARGeTeD THeRAPieS  
iN SCCHN
Cetuximab
Cetuximab was the first targeted therapy approved in the first line 
for R/M SCCHN, conferring survival benefits in combination 
with platinum-based CT (7, 9, 19–21). SCCHN tumors are heav-
ily influenced by dysregulation of the epidermal growth factor 
receptor (EGFR) pathway, and high EGFR expression is related 
to worse outcomes (22). Cetuximab is an immunoglobulin G sub-
class 1 (IgG1) monoclonal antibody (mAb) targeting the EGFR 
by preventing its ligand-mediated activation and dimerization, 
and it thus inhibits tumor cell proliferation and stimulates proa-
poptotic pathways within the tumor cell (23–25). Furthermore, 
cetuximab limits EGFR’s potential for translocation into the cell 
nucleus and leads to inhibition of double-stranded DNA break 
repair by preventing activation of the DNA-dependent protein 
kinase. This activity may also have an effect on pathways of tumor 
metastasis (26, 27). Finally, the IgG1 isotype allows cetuximab to 
induce antibody-dependent cell-mediated cytotoxicity (ADCC), 
which is the process of immune cells targeting and killing cells 
coated in IgG1 or other isotypes of antibodies (23, 28, 29). In 
addition to its apoptosis-inducing, EGFR-blocking activity, 
cetuximab directs the ADCC mechanism at tumor cells, using 
primarily natural killer (NK) cells to maximize antitumor effects 
and thereby representing the first immunotherapy in SCCHN 
(Figure 2) (20, 24, 30, 31).
FiGURe 1 | New continuum of care for R/M SCCHN. New drugs are under investigation in SCCHN and will change the treatment landscape for R/M disease. 
There are now multiple lines of treatment that constitute a continuum of care. The objective of this paper is to define the position of these new drugs in the current 
treatment landscape. The algorithm for unfit patients’ needs to be further established in prospective trials. CT, chemotherapy; EXTREME, cetuximab plus cisplatin/
carboplatin plus 5-fluorouracil followed by maintenance cetuximab; PCE, paclitaxel, carboplatin, and cetuximab, followed by cetuximab maintenance until 
progressive disease or toxicity; R/M, recurrent and/or metastatic; SCCHN, squamous cell carcinoma of the head and neck; TPEx, cisplatin, docetaxel, cetuximab. 
*Other first-line options include cetuximab + cisplatin, cetuximab + paclitaxel and other platinum-based treatments. †Supported by phase 3 trial evidence.
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Multiple preclinical studies have demonstrated cetuximab’s 
ability to stimulate ADCC and affect antitumor immunity. In vitro 
evidence shows that cetuximab can mobilize NK cells, activate 
neutrophils, and stimulate dendritic cell maturation (20, 23, 
29, 30). Furthermore, cetuximab treatment results in an 
increase in cytotoxic CD8+ T cells in peripheral blood samples 
from patients with SCCHN receiving weekly cetuximab plus 
chemoradiotherapy during clinical trials (23). Finally, enhanced 
cytotoxic activity has been documented by ex vivo ADCC assays 
in patients with R/M SCCHN receiving cetuximab-based therapy, 
and induced ADCC was shown to be associated with positive 
clinical outcomes (20). Although it is challenging to prove in 
clinical studies, data suggest that this property may be involved 
in cetuximab’s antitumor activity in humans (23, 24, 29, 30, 32). It 
has also been proposed that stimulation of ADCC is an underly-
ing mechanism for cetuximab’s clinically meaningful activity 
and the comparatively notable response rates with first- and 
second-line treatment in patients with R/M SCCHN, which set it 
apart from other mAb EGFR inhibitors (e.g., panitumumab) (33). 
Cetuximab can be distinguished from panitumumab in terms of 
their differential effect on the immune system. Panitumumab, an 
IgG2 antibody with weak ADCC action, had lower clinical activity 
as monotherapy (34) and in combination regimens (SPECTRUM, 
and other) (35) in R/M SCCHN. Therefore, the advantage in 
meaningful clinical activity of cetuximab over panitumumab in 
SCCHN may be partially attributed to their effects beyond EGFR 
inhibition (notably, panitumumab is a very potent EGFR inhibi-
tor), i.e., to the differential induction of immune response, which 
seems to be highly relevant in SCCHN (Figure 2) but less relevant 
in colorectal cancer.
In SCCHN, a highly immunogenic disease, combinations of 
immunotherapies such as ICIs, antitumor vaccines, cetuximab 
(through ADCC action), and engineered T  cells may have the 
potential to further improve standard response rates (31). It is 
also reasonable to propose that “priming” antitumor immune 
responses with cetuximab prior to the administration of other 
immunotherapies might augment a patient’s responsiveness 
to treatment (31, 36). Contribution of ADCC to the antitumor 
activity of cetuximab have not been widely tested in clinical trials, 
but recent studies has suggested a correlation between cetuximab 
efficacy and high ADCC (37, 38).
immune Checkpoint inhibitors
ICIs are a new class of therapeutics in cancer. They function 
via the interruption of immunosuppressive pathways, called 
inhibitory checkpoints, which are normally used by tumor cells 
to prevent detection and elimination by the host immune sys-
tem (31, 39). Molecular targets of ICIs found on T cells include 
cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed 
cell death protein 1 (PD-1) receptor. A third common target 
is PD-1’s corresponding ligand, PD-L1, found on both tumor 
and immune cells (31, 39). ICIs are projected to be particularly 
successful in tumors with high levels of endogenous PD-L1 
expression, including SCCHN (31). A full list of ICIs currently 
in advanced clinical trials for SCCHN can be found in Table 1, 
including anti-PD-1 antibodies nivolumab and pembrolizumab, 
as well as the anti-PD-L1 antibodies durvalumab and avelumab. 
Newer agents targeting immuno-inhibitory (VISTA, Tim-3, 
LAG3) or stimulatory (CD137, GITR, OX-40) molecules are 
also being studied (40). As of this writing, the bulk of available 
TABLe 1 | PD-1 axis immune checkpoint inhibitors under development for recurrent or metastatic squamous cell carcinoma of the head and neck.
Name Sponsor isotype Target Phase Schedule used in clinical study Regimen
Atezolizumab Genentech IgG1 PD-L1 1 0.01–20 mg/kg q3w Monotherapy
1/2 1,200 mg Combination with anti-CD27
Avelumab Merck KGaA IgG1 PD-L1 1 1–20 mg/kg q2w (41) Monotherapy
Pfizer 1 N/A Combination with anti-OX40
1 N/A Combination with anti-4-1BB
Durvalumab MedImmune IgG1 PD-L1 3 1,500 mg q4w (42) Monotherapy
3 1,500 mg q4w (42) Combination with anti-CTLA-4
1 N/A Combination with anti-CTLA-4 and  
chemotherapy (CT)
Ipilimumab Bristol-Myers Squibb IgG1 CTLA-4 3 N/A Combination with anti-PD-1
1 3 mg/kg q3w (43) Combination with anti-B7-H3
Nivolumab Ono/Bristol-Myers Squibb IgG4 PD-1 3 3 mg/kg q2w (44) Monotherapy
3 N/A Combination with anti-CTLA-4
Pembrolizumab MSD IgG4 PD-1 3 200 mg q3w (45) Monotherapy
3 200 mg q3w (46) Combination with CT
1 2 mg/kg q3w (47) Combination with anti-B7-H3
2 2 mg/kg q3w Combination with anti-EGFR
Tremelimumab AstraZeneca IgG2 CTLA-4 2 N/A Monotherapy
3 75 mg q4w (42) Combination with anti-PD-L1
1 N/A Combination with anti-PD-L1 and CT
CD, clusters of differentiation; CTLA-4, cytotoxic T-lymphocyte antigen-4; EGFR, epidermal growth factor receptor; IgG, immunoglobulin G; N/A, not available; PD-1, programmed 
cell death protein 1; PD-L1, programmed cell death ligand 1; q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks.
FiGURe 2 | Mechanism for cetuximab-mediated antibody-dependent cell-mediated cytotoxicity stimulation. CD, clusters of differentiation; EGFR, 
epidermal growth factor receptor; IFN-γ, interferon-γ; NK, natural killer; PD-L1, programmed cell death ligand 1.
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TABLe 2 | Cetuximab-based therapy options for first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.
Name Regimen Median PFS, 
months
Median OS, 
months
ORR, % Dosage details
EXTREME (n = 442) Cetuximab + cisplatin/
carboplatin + 5-FU
5.6 10.1 36 •	 Cisplatin (100 mg/m2 on day 1) or carboplatin (AUC 5 mg/
mL/min, as a 1-h intravenous infusion on day 1)  
and 5-FU (1,000 mg/m2 per day for 4 days) every  
3 weeks for a maximum of 6 cycles
•	 Cetuximab (initial dose of 400 mg/m2 as a 2-h  
intravenous infusion, then 250 mg/m2 as a 1-h  
intravenous infusion per week) for a maximum of 6 cycles
PCE (n = 45) Cetuximab + carboplatin 
+ paclitaxel
5.2 14.7 40 •	 Paclitaxel (100 mg/m2 on day 1 and 8) and carboplatin  
(AUC 2.5 on day 1 and 8), repeated every  
3 weeks for up to 6 cycles
•	 Cetuximab (initial dose of 400 mg/m2, followed by  
250 mg/m2 weekly) until PD or unacceptable toxicities
TPEx (n = 54) Cetuximab + cisplatin  
+ docetaxel
6.2 14 44.4 •	 Docetaxel and cisplatin (75 mg/m2 both) on day 1
•	 Weekly cetuximab 250 mg/m2 (initial dose  
of 400 mg/m2)
•	 Treatment was repeated every 21 days for  
4 cycles, followed by maintenance cetuximab  
(500 mg/m2) every 2 weeks until PD or unacceptable toxicity
Burtness et al. (50) 
(n = 117)
Cetuximab + cisplatin 4.2 9.2 26 •	 Cetuximab was given (dose of 200 mL/m2)  
intravenously on day 1 over 120 min for 1 cycle only;  
subsequent cycles were administered at  
125 mL/m2/week intravenously over 60 min
•	 Cisplatin (100 mg/m2) was given on day  
1 every 4 weeks
Hitt et al. (51) (n = 46) Cetuximab + paclitaxel 4.2 8.1 54 •	 Paclitaxel (80 mg/m2) and cetuximab  
(initial dose 400 mg/m2, subsequent  
doses of 250 mg/m2) were given weekly  
until PD or unacceptable toxicity
5-FU, 5-fluorouracil; AUC, area under the curve; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
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data on the efficacy of ICIs in SCCHN are derived from trials 
with platinum-refractory and second- or later-line R/M SCCHN 
patient populations predominantly with an Eastern Cooperative 
Oncology Group performance status (ECOG PS) of 0 or 1.
FiRST-LiNe TReATMeNT OPTiONS  
iN R/M SCCHN
For decades prior to the introduction of the EXTREME regimen 
[platinum, 5-FU, cetuximab, followed by maintenance cetuximab 
until progressive disease (PD) or toxicity], no experimental treat-
ments yielded any significant increase in survival in patients with 
R/M SCCHN.
EXTREME was a randomized phase 3 trial published in 2008, 
and the EXTREME regimen became the first to improve PFS and 
OS in patients with R/M SCCHN (Table  2) (9, 48). The study 
included fit patients (n = 442) with R/M SCCHN, of whom 88% 
had ECOG PS 0–1/Karnofsky score ≥80 and 12% had ECOG PS 
2/Karnofsky score <80, who were ineligible for local therapy. The 
main exclusion criteria were surgery or irradiation within the pre-
vious 4 weeks, or previous systemic therapy unless it was part of 
a multimodal treatment for LA disease that had been completed 
>6 months before study entry (9). The trial investigated whether 
the addition of cetuximab to platinum-based CT with cisplatin or 
carboplatin plus 5-FU followed by maintenance cetuximab until 
PD or toxicity in the first line would improve survival in patients 
with R/M SCCHN. The primary endpoint of the EXTREME study 
was OS, which it met as median OS was significantly improved 
from 7.4 to 10.1  months [hazard ratio (HR) =  0.80 (95% CI, 
0.64–0.99)] in the CT and cetuximab plus CT arms, respectively 
(9). Median PFS was also significantly improved by the addition 
of cetuximab to first-line CT, from 3.3 to 5.6 months [HR = 0.54 
(95% CI, 0.43–0.67)] (9). The ORR in patients with R/M SCCHN 
was nearly doubled upon the addition of cetuximab to CT [36 
vs 20%; odds ratio = 2.33 (95% CI, 1.50–3.60)] (9). Finally, the 
addition of cetuximab to platinum-based CT led to a significant 
reduction in pain and in problems with social eating and speech, 
thereby positively impacting social functioning and quality of life 
for patients receiving this treatment (49). The toxicity profile of 
the EXTREME regimen has been shown to be predictable and 
manageable (9).
It is important to note that patients eligible for the EXTREME 
regimen in first-line R/M SCCHN are not necessarily treatment-
naïve and may have received previous platinum-containing 
therapy (but ≥6 months previously) in the LA SCCHN setting 
(9, 52–54). The role of cetuximab in first-line R/M SCCHN spe-
cifically for patients who have previously received cetuximab for 
LA SCCHN has not been fully investigated, although responsive-
ness to retreatment in such patients has been documented (55). 
In addition, the importance of polychemotherapy in combination 
with cetuximab is suggested when considering data from the 
randomized trial by Burtness et  al., in which cetuximab plus 
6Argiris et al. Treatment Options in R/M SCCHN
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cisplatin showed improved activity in first-line R/M SCCHN 
(ORR was ≥2.5-fold higher in the cetuximab plus cisplatin arm), 
but did not show statistically significant OS benefits compared 
with cisplatin monotherapy. The results of this trial, however, 
are difficult to interpret definitively due to the small sample size 
(n = 117 patients) (50).
Over the past decade, retrospective and observational stud-
ies have consistently confirmed the benefits of the EXTREME 
regimen in patients with first-line R/M SCCHN (9, 11, 56). In the 
DIRECT study, prospective data were collected for 154 patients 
with untreated SCCHN in the R/M setting receiving cetuximab 
according to the EXTREME regimen guidelines (53). The 
EXTREME regimen was shown to be feasible in everyday clinical 
practice and yielded a median time to progression of 6 months, 
which is in line with PFS findings in the EXTREME study (9, 
11, 56). Siano et al. have also shown benefits of such regimens in 
a retrospective analysis of 117 patients treated with cetuximab 
plus platinum-based CT with or without 5-FU in first-line R/M 
SCCHN (57). The median OS of 12.4 months was in line with OS 
findings for cetuximab plus platinum-based CT in clinical trials 
(9, 11, 56). Median PFS and OS during follow-up second-line 
treatment with methotrexate, paclitaxel, or other agents were 
between 2.6 and 6.1  months, showing the need for stronger 
options in later-line treatments of R/M SCCHN. De Mello et al. 
also conducted a retrospective study of 121 patients receiving the 
EXTREME regimen as first-line treatment in the R/M SCCHN 
setting (58). Median PFS and OS were 8 and 11 months, respec-
tively, which are also in line with findings for cetuximab plus 
platinum-based CT in clinical trials (9, 11, 56). Similarly, in a 
retrospective study of 31 patients with R/M SCCHN, cetuximab 
plus CT followed by maintenance with biweekly cetuximab led 
to a stable disease rate of 52%, partial response rate of 39%, 
and complete response rate of 9% (59). Furthermore, there is 
evidence that maintenance therapy until PD with cetuximab as 
a single agent following the EXTREME regimen is also well-
tolerated with a good compliance (relative dose intensity = 82%) 
(53, 59). Indeed, in the EXTREME trial, the frequency of severe 
skin reactions in the cetuximab-containing arm decreased from 
9 to 5% during the cetuximab maintenance phase (median treat-
ment duration = 29.9 weeks) (60).
It is important to point out that in SPECTRUM, an analogous 
phase 3 study to the EXTREME trial, the addition of the anti-
EGFR mAb panitumumab to cisplatin and 5-FU yielded a statisti-
cally significant improvement in PFS (5.8 vs 4.6 months) and ORR 
(36 vs 25%), but not in OS (35). These data confirm the utility of 
anti-EGFR therapy in first-line treatment of R/M SCCHN, while 
also suggesting that cetuximab and panitumumab, an IgG1 and 
an IgG2 mAb, respectively, do not produce identical survival 
outcomes in patients with SCCHN. As previously discussed, 
these differential outcomes could be partially attributed to the 
distinct property of ADCC stimulation by cetuximab (Figure 2) 
that potentially enhances antitumor activity in SCCHN.
Using a Taxane instead of 5-FU  
in the Backbone Regimen
Chemotherapy backbones for the EXTREME regimen can be 
altered according to patient needs by substituting a taxane for 
5-FU to boost response rates and/or circumvent contraindica-
tions to 5-FU (61). Details on regimens and doses are outlined in 
Table 2. The TPE (cisplatin, docetaxel, cetuximab) combination 
regimen was originally introduced by Argiris et al. in a phase 2 
trial in LA SCCHN (62) and was subsequently investigated in the 
phase 2 GORTE C 2008-03 study (the so-called “TPEx” regimen) 
in the first-line treatment of R/M SCCHN (56). After four cycles 
of TPEx, patients without PD received maintenance cetuximab 
every 2 weeks until PD. The GORTEC 2008-03 study included a 
similar patient population to the EXTREME study, i.e., patients 
with previously untreated R/M SCCHN, except for any treatment 
received in the LA setting ≥6 months prior to study entry. ORR 
in patients who received TPEx was 44.4%, and median OS was 
14  months. The PCE regimen similarly consists of paclitaxel, 
carboplatin, and cetuximab followed by cetuximab maintenance 
until PD or toxicity (Table  2) (11). A trial of PCE, which was 
presented at the 2016 annual meeting of the American Society 
of Clinical Oncology (ASCO), also included patients who 
were EXTREME eligible and received PCE as first-line treat-
ment for R/M SCCHN. ORR was 40% and the median OS was 
14.7 months. Finally, a phase 2 study found that cetuximab plus 
weekly paclitaxel given in the first line yielded an ORR of 54% 
and 10 complete responses (22% of the patient population of 
the trial) (51). Overall, cetuximab plus CT-based treatments for 
first-line R/M SCCHN are associated with high ORRs, extending 
OS and permitting a large number of patients to achieve disease 
control. Therefore, in cases of PD on this first-line treatment, 
a high number of patients have been able to enter second-line 
therapy. Finally, it is important to note that an ongoing phase 2 
trial led by GORTEC is comparing TPEx with EXTREME in the 
first-line treatment of R/M SCCHN (NCT02268695), with OS 
as the primary endpoint and ORR, PFS, and safety as secondary 
outcomes. The results of this trial will prove very informative to 
oncologists when deciding which regimen is more appropriate 
for their patients, except in clear cases where the patient has a 
contraindication to 5-FU.
Management of Unfit Patients
Although a patient with an ECOG PS of 0 or 1 would receive 
the EXTREME regimen in the first line, a patient with an ECOG 
PS of 2 would generally be placed on a single-agent therapy in 
the first line, including, but not limited to, targeted therapeutics 
such as cetuximab or cytotoxic CT agents such as methotrexate, 
docetaxel, paclitaxel, carboplatin, 5-FU, and capecitabine (9, 52, 
54, 61). Another option may be the combination of cetuximab 
with a taxane for selected patients. However, there are no data 
showing benefit from any of these treatments (monotherapy or 
combination) in a controlled, randomized trial. For example, 
a phase 3 trial that compared gefitinib with methotrexate (the 
IMEX trial) and another that compared docetaxel with or without 
gefitinib, which both enrolled some patients with an ECOG PS 
of 2, failed to show survival benefits with these newer therapies 
over standard monotherapy with methotrexate or a taxane 
(63, 64). Zalutumumab, an anti-EGFR antibody, did not result in 
prolonged OS compared with best supportive care (BSC) alone 
(many patients received methotrexate in the control arm) in a 
patient population with platinum-refractory R/M SCCHN, which 
TABLe 3 | Ongoing studies with immune checkpoint inhibitors in first-line R/M SCCHN vs standard of care (eXTReMe regimen).
NCT # immunotherapy agent(s) in study Phase Population Arms
NCT02741570  
(CheckMate 651)
Nivolumab, ipilimumab 3
Previously untreated R/M 
SCCHN, ≥6 months since 
last dose of platinum
Nivolumab + ipilimumab vs EXTREME
NCT02358031 
(KEYNOTE-048)
Pembrolizumab 3 Pembrolizumab vs Pembrolizumab + CT vs EXTREME
NCT02551159 (KESTREL) Durvalumab, Tremelimumab 3 Durvalumab vs Durvalumab + tremelimumab vs 
EXTREME
CT, chemotherapy; EXTREME, cetuximab plus cisplatin/carboplatin plus 5-fluorouracil followed by maintenance cetuximab; NCT, ClinicalTrials.gov identifier; R/M SCCHN, recurrent 
or metastatic squamous cell carcinoma of the head and neck.
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included patients with an ECOG PS of 2 (16). First-line cetuxi-
mab vs methotrexate monotherapy is currently being evaluated 
in the unfit elderly (≥70  years of age) with R/M SCCHN in a 
randomized phase 3 trial (ELAN-UNFIT, NCT01884623).
The use of ICI monotherapy for the treatment of unfit patients 
is of interest and deserves clinical study. Given their preferable 
toxicity profile and documented activity in SCCHN, we propose 
that ICIs can be potentially incorporated in the therapeutic 
algorithm (Figure 1). However, it should be recognized that the 
activity of ICIs as monotherapy is low and the majority of patients 
progress at first reevaluation; therefore, symptomatic patients 
with PS of 2 due to disease may deteriorate rapidly.
Status of iCi Clinical Trials for  
First-Line Treatment
Immune checkpoint inhibitors such as nivolumab, pembroli-
zumab, and durvalumab are currently being investigated in the 
first-line R/M SCCHN setting for fit patients, with the EXTREME 
regimen chosen as a comparator arm in several recently opened 
phase 3 trials (Table 3). Nivolumab in combination with the anti-
CTLA-4 antibody ipilimumab is compared with the EXTREME 
regimen in the CheckMate 651 trial. In contrast, pembrolizumab 
is being investigated as a monotherapy as well as in combination 
with CT for first-line R/M SCCHN (KEYNOTE-048). Finally, 
durvalumab is under examination as a monotherapy and in 
combination with the anti-CTLA-4 antibody tremelimumab (the 
KESTREL study). However, no results are yet available from these 
trials as of the time of this writing and, therefore, use of ICIs in 
first-line R/M setting is not recommended outside of clinical 
trials (13, 14, 42, 46, 65, 66). Finally, it is worth noting that a 
recent trial showed no improvement in outcomes by adding an 
immunotherapeutic agent (motolimod) to the EXTREME regi-
men as quadruplet therapy in first-line R/M SCCHN (67).
SeCOND-LiNe AND PLATiNUM-
ReFRACTORY OPTiONS iN R/M SCCHN
Over the past decade, patients with second-line R/M SCCHN 
predominantly received either single-agent CT or BSC, or they 
entered clinical trials (52, 54). Pembrolizumab and nivolumab 
were granted US Food and Drug Administration approval in 2016 
(August and November, respectively) for use in patients with R/M 
SCCHN who progress on or after platinum-based CT, with no 
PD-L1 testing requirement in place.
For the purposes of this review (and based on patient selection 
criteria for these trials), fit patients who progress on EXTREME 
first-line therapy in the R/M setting will be considered as entering 
second- or later-line therapy for R/M SCCHN (52, 54). Fit patients 
who progress within 6 months after the last administered dose 
of platinum (cisplatin or carboplatin) in either the LA or R/M 
setting are, due to this very short duration since the last platinum 
treatment, not optimal candidates for platinum retreatment. 
These patients have been referred to as “platinum-refractory” 
(i.e., also EXTREME-ineligible). Treatment options are very 
similar between patients with platinum-refractory disease and 
those in second-line R/M SCCHN and, therefore, these two 
patient subgroups will be discussed together here and labeled as 
“second-line” (68–70). Moreover, most of the second-line trials 
in R/M SCCHN have traditionally allowed any number of prior 
therapies for R/M disease and, therefore, in these trials, “second-
line” therapy implies “second-line and beyond.” Although not 
the principal focus of this review manuscript, we will also briefly 
discuss recent observations involving kinase inhibitors such as 
afatinib (a pan-human EGFR inhibitor, which blocks tyrosine 
kinase function in human EGFR 1, 2, and 4) and buparlisib 
[targeting phosphoinositol-3-kinase (PI3K)].
Chemotherapy
Available agents for second-line therapy in R/M SCCHN include 
methotrexate, docetaxel, and paclitaxel. ORR to methotrex-
ate monotherapy in the second line is 6%, and median OS is 
≈6.0 months (15, 63). Second-line treatment with a taxane, such 
as docetaxel or paclitaxel, is frequently used in R/M SCCHN 
but has not been demonstrated to be superior to other agents in 
this setting (16, 61, 64). Additionally, while the CheckMate 141 
trial was not designed to compare the three regimens used in the 
comparator arm, docetaxel appeared slightly and numerically 
superior to methotrexate (and possibly cetuximab, although only 
15 patients received this treatment) in terms of OS, although no 
concrete conclusions can be drawn, and phase 2 randomized tri-
als suggest no difference in survival between these monotherapies 
(44, 71). Irinotecan has also shown some very limited activity in 
this setting (7). Combination therapy does not appear to yield 
better results than monotherapy as a second-line treatment for 
patients with R/M SCCHN. A phase 2 trial of irinotecan and 
docetaxel that enrolled patients with good performance status 
in second-line treatment showed poor results with an objective 
response rate of 3% and a median survival of 5  months (70). 
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Patients who received BSC for the sole purpose of symptom 
management also attained a median OS of ≈5 months (16).
Anti-eGFR Therapy
Retreatment with platinum in the setting of platinum-refractory 
disease increased toxicity without improving efficacy outcomes 
(5, 72). Cetuximab plus cisplatin or carboplatin in platinum-
refractory patients within 50  days of the last platinum dose 
of the previous regimen in the R/M setting achieved ORRs of 
10% with a median OS of ≈6 months (5). Herbst et al. reported 
an ORR to cetuximab plus cisplatin of 6% and a median OS 
of 4.3  months in patients with platinum-refractory disease if 
PD occurred within 90 days of the last platinum dose prior to 
entering the study (73).
Cetuximab monotherapy in second-line and platinum-
refractory R/M SCCHN populations has been tested in 3 phase 
2 clinical trials by Vermorken et  al., Baselga et  al., and Herbst 
et  al., involving patients who had progressed on cisplatin- or 
carboplatin-based regimens (5, 12, 72, 73). ORRs of 10–13% were 
observed. Disease control rates while on cetuximab monotherapy 
can top 50%, with median OS of between 5 and 6  months (7, 
12, 61, 72). Currently, cetuximab monotherapy is approved in the 
US but has not been compared with BSC as of yet.
Finally, as in the first line, cetuximab plus paclitaxel is also 
a palliative option in the second-line setting, offering ORRs of 
38–55% and median OS of 7.6–10 months (74–76). Cetuximab 
plus docetaxel given to patients with R/M SCCHN after failure of 
platinum-based therapy resulted in 11% of patients achieving par-
tial responses and 40% achieving stable disease. Disease control 
rates were similar between patients with platinum-sensitive and 
platinum-refractory disease, and median OS was 6.7 months (77).
Other anti-EGFR therapies have failed to offer higher efficacy 
results. Second-line panitumumab monotherapy yielded an ORR 
of 4% and a median OS of 5.1 months in the PRISM study (34). 
Non-mAb EGFR tyrosine kinase inhibitors such as gefitinib, 
erlotinib, lapatinib, and afatinib have also yielded results that 
must be regarded as modest at best. In a randomized phase 3 
trial, patients who had progressed on or were not fit for standard 
first-line therapy received docetaxel plus a placebo or docetaxel 
plus gefitinib. ORRs for the docetaxel plus placebo vs docetaxel 
plus gefitinib arms were 6.2 and 12.5%, respectively, with a 
non-significant improvement in median OS of 1.3 months (from 
6.0 to 7.3 months). Similar results have been obtained from the 
LUX-Head and Neck 1 trial with afatinib. LUX1 was a randomized 
phase 3 trial comparing afatinib vs methotrexate in fit patients with 
R/M SCCHN who had progressed on or after first-line platinum-
based therapy. When compared with the efficacy of methotrexate 
monotherapy described above, afatinib yielded a median OS of 
6.8 months (no improvement), with an ORR of 10% (15, 63, 64). 
Therefore, afatinib has no survival advantage over methotrexate 
in this setting and cannot be considered as an evidence-based 
approach in second-line therapy. Another phase 2 trial showed 
comparable efficacy with some toxicity profile differences between 
cetuximab and afatinib (78). Whether selected patients may ben-
efit from afatinib (e.g., those with p16-negative disease) has yet to 
be demonstrated in prospective clinical trials (79).
Pi3K inhibition
Advances are being made in the use of PI3K inhibition in 
second- or later-line R/M SCCHN therapy. Because the PI3K/
Akt/mTOR pathway is a signaling cascade downstream of the 
EGFR that stimulates cell growth and is often dysregulated in 
tumor cells, targeting this pathway is one potential method for 
overcoming resistance to anti-EGFR targeted therapy (80). The 
BERIL-1 trial of the pan-PI3K inhibitor buparlisib (BKM120) 
in second- and third-line settings was presented at ASCO 2016. 
Buparlisib plus paclitaxel treatment was compared to a placebo 
plus paclitaxel regimen in platinum-pretreated patients with one 
or two previous lines of therapy in the R/M SCCHN setting. The 
response rate to buparlisib plus paclitaxel was 39% (vs 14% in 
the comparator arm), with patients achieving a median OS of 
10.0  months on this treatment (vs 6.5  months; no indicator of 
statistical significance was presented) (81).
iCi Therapy
Currently, ICIs present an efficacious therapeutic option for 
patients with R/M SCCHN who have progressed after platinum-
based therapy, which supports the emergence of a continuum of 
care for R/M disease (Figure 1).
Pembrolizumab and nivolumab approvals in the US for patients 
with R/M SCCHN who progress on or after platinum-containing 
treatment were based on results from the KEYNOTE-012 and 
CheckMate 141 trials. KEYNOTE-012, a non-randomized phase 
1b trial with pembrolizumab monotherapy, enrolled 192 patients. 
The first 60 patients (“Cohort B”) were selected for PD-L1–positive 
tumors and treated with 10 mg/kg pembrolizumab intravenously 
every 2  weeks, and the remaining 132 patients (“Cohort B2”) 
were unselected for tumor PD-L1 expression and treated with 
pembrolizumab at a fixed dose of 200  mg intravenously every 
3 weeks (13, 45, 82). Among Cohort B patients (i.e., patients with 
PD-L1-positive tumors), 70% had received ≥2 lines of therapy 
(13). For this cohort, median PFS and OS were 2 and 13 months, 
respectively. In Cohort B2, i.e., patients unselected for PD-L1 
expression status, 18% had not received prior therapy in the R/M 
setting, while 57% had received ≥2 lines of therapy (45). These 
patients achieved a median PFS of 2 months and median OS of 
8 months, with tolerable safety. The observed ORR was 18% in 
both cohorts (45, 82).
CheckMate 141 was a phase 3 trial that enrolled 361 patients 
with R/M SCCHN, of any tumor PD-L1 expression status, who 
had disease progression within 6 months after platinum-based CT 
(Table 4) (44). Nivolumab 3 mg/kg every 2 weeks was compared to 
the investigator’s choice (IC) of standard therapy (methotrexate, 
docetaxel, or cetuximab). Nivolumab monotherapy yielded supe-
rior OS over standard therapy with a median OS of 7.5 months 
(vs 5.1 months with standard therapy) with an HR for death, 0.70 
(p = 0.01). However, the median PFS was similar in the two arms 
(2 months with nivolumab and 2.3 months with standard therapy, 
HR for disease progression or death, 0.89; p = 0.32) and the ORR 
was 13.3% with nivolumab vs 5.8% with standard therapy (44). 
Notably, at 6 months, the rate of PFS was 19.7% with nivolumab 
vs 9.9% with standard therapy, whereas at 1 year, the rate of OS 
was 36% with nivolumab vs 16.6% with standard therapy.
TABLe 5 | Available data for immune checkpoint inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head  
and neck (14, 67, 80).a
NCT # No. of 
Patients
eligibility Drug Available data Toxicity findings
Median 
PFS, 
months
Median 
OS, 
months
ORR, %
NCT02105636 (CheckMate 
141) (67)
361 Nivolumab 2 7.5 13.3 13.1% of patients experienced grade 3–4 TRAEs
2 patients died due to TRAE (1 pneumonitis and 1 
hypercalcemia)
NCT01848834 (expanded 
KEYNOTE-012) (80)
60 PD-L1+ Pembrolizumab 2 13 18 17% of patients experienced grade 3–4 TRAEs
132 Any PD-L1 
status
2 8 18 No treatment-related deaths were reported
About 9% of patients experienced grade 3–4 TRAEs
No treatment-related deaths were reported
NCT02255097 
(KEYNOTE-055) (14)
171 Pembrolizumab 2.1 8 16 26 patients (15%) experienced grade 3–5 TRAEs
1 patient died of treatment-related pneumonitis
NCT, ClinicalTrials.gov identifier; ORR, overall response rate; OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; TRAE, treatment-related 
adverse event.
aThe values in this table reflect the PFS, OS, and ORR recorded for the populations of each trial regardless of PD-L1 expression status (14, 67, 80).
TABLe 4 | Studies with immune checkpoint inhibitors in mixed-, second-, and later-line settings and platinum-refractory R/M SCCHN.
NCT # Drug Phase Population Arms
NCT02105636  
(CheckMate 141)
Nivolumab 3 (completed) •	 Platinum-refractory
•	 Second-/later-line R/M SCCHN
Nivolumab vs IC (cetuximab or docetaxel or 
methotrexate)
NCT01848834 
(KEYNOTE-012)
Pembrolizumab 1b •	 Previously untreated R/M SCCHN, ≥6 months 
since last dose of platinum
•	 Platinum-refractory
•	 Second-/later-line R/M SCCHN
Pembrolizumab monotherapy
NCT02255097a 
(KEYNOTE-055)
Pembrolizumab 2 •	 Platinum-refractory
•	 Second-/later-line R/M SCCHN
Pembrolizumab monotherapy
NCT02252042 
(KEYNOTE-040)
Pembrolizumab 3 •	 Platinum-refractory
•	 Second-/later-line R/M SCCHN
Pembrolizumab vs IC (cetuximab or docetaxel or 
methotrexate)
NCT02823574  
(CheckMate 714)b
Nivolumab, 
ipilimumab
2 •	 Previously untreated R/M SCCHN, ≥6 months 
since last dose of platinum
•	 Platinum-refractory
Nivolumab + ipilimumab vs Nivolumab + placebo
NCT02369874 (EAGLE) Durvalumab 3 •	 Platinum-refractory
•	 Second-/later-line R/M SCCHN
Durvalumab vs Durvalumab + tremelimumab 
vs IC (fluoropyrimidine, cetuximab, taxane, or 
methotrexate)
tremelimumab
NCT02207530 (HAWK) Durvalumab 2 •	 Platinum-refractory
•	 Second-/later-line R/M SCCHN
Durvalumab monotherapy
IC, investigator’s choice; NCT, ClinicalTrials.gov identifier; R/M SCCHN, recurrent and/or metastatic squamous cell carcinoma of the head and neck.
aAll patients in KEYNOTE-055 were also cetuximab-refractory.
bCheckMate 714 enrolls a cohort of patients in the first-line setting.
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Safety findings from ICI studies with available data indicated 
a favorable and tolerable toxicity profile for pembrolizumab 
and nivolumab over standard therapies in second-line and 
platinum-refractory R/M SCCHN (Table 5). Treatment-related 
events occurred in 58.9% (grade 3–4 in 13.1%) and 62% (grade 
3–4 in 9%) of patients in CheckMate 141 and KEYNOTE-012, 
respectively (44, 45). Finally, patient-reported outcomes from 
CheckMate 141 revealed stabilization or slight improvement 
in quality of life measures such as social functioning and pain, 
while IC monochemotherapy resulted in a clinically meaningful 
worsening across many of the same measures (44).
Although ICIs may not improve median PFS, as compared 
to IC therapy (Table  5) (13, 14, 31, 65), the subset of patients 
who achieve a response or stable disease on ICI treatment tend 
to experience a longer duration of response and OS than is to 
be expected with standard CT (14, 82, 83). For patients with 
SCCHN, ORRs to ICI monotherapy range from 13 to 18% 
(Table  4). Somewhat higher tumor responses and survival are 
seen with positive tumor PD-L1 expression status even though 
patients with PD-L1-negative tumors may also benefit (84).
Other trials of ICI monotherapy are also tackling second-
line R/M SCCHN (patient inclusion criteria in Table 4 and full 
data summary in Table 5). Ongoing trials with pembrolizumab 
include KEYNOTE-040 and MASTERKEY232 (combination 
pembrolizumab and talimogene laherparepvec in second-line 
and platinum-refractory R/M SCCHN). Upcoming nivolumab 
trials in SCCHN include CheckMate 714 (mixed population of 
patients with platinum-refractory and first-line R/M SCCHN). 
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Finally, ongoing trials with durvalumab include the phase 2 
HAWK study (monotherapy in second-line, PD-L1-positive 
R/M SCCHN following a single platinum-based treatment), and 
the phase 3 EAGLE study (monotherapy or combination with 
tremelimumab in second-line R/M SCCHN following a single 
platinum-based treatment) (14, 65, 66, 85, 86).
Patient Selection for iCi Therapy: PD-L1 
and p16/Human Papillomavirus (HPv) 
Status and Other Biomarkers
Based on the available clinical trial-generated evidence, ICIs 
present a promising new opportunity for a small number of 
patients with very advanced disease who progress on standard 
therapy. ORRs to ICIs remain around the 20% mark in second-
line patients with R/M SCCHN unselected for tumor PD-L1 
expression status. Although data continue to suggest that PD-L1 
expression correlates with better efficacy to ICIs, the correlation 
is not definitive and no other reliable biomarker for effectively 
selecting optimally responsive patient subgroups has been identi-
fied as of yet (31, 83). Until additional reliable biomarkers for the 
efficacy of PD-1/PD-L1 blockade are identified, patient selection 
for pembrolizumab, durvalumab, and nivolumab therapy remains 
unsatisfactory. In the CheckMate 141 trial, positive tumor PD-L1 
expression appeared to have conferred a numerically higher 
survival benefit in patients receiving nivolumab vs IC therapy 
[HR = 0.55 (95% CI, 0.36–0.83) in patients with tumors express-
ing ≥1% PD-L1 vs HR = 0.89 (95% CI, 0.54–1.45) in patients with 
tumors expressing <1% PD-L1] (44, 65). However, it is important 
to note that the trial was not powered to detect interactions 
between tumor PD-L1 expression status and treatment. Subgroup 
analyses of KEYNOTE-012 also indicated higher OS and ORR in 
patients with ≥1% PD-L1-expressing tumors who had received 
≥1 dose of pembrolizumab (45, 87). When immune cells were 
included in the PD-L1 expression analysis, ORR rose to 22% in 
patients with PD-L1-expressing tumors but dropped to 4% in 
those with <1% PD-L1 expression (45). The predictive value of 
tumor PD-L1 expression continues to be investigated. Prospective 
trial populations will need to be large enough to detect such an 
interaction because the sample sizes in trials completed to this 
date have been relatively small. Furthermore, there are currently 
multiple methodologies available for assessing PD-L1 positivity 
and some controversy exists about which cells should be included 
in such an analysis (88). Future trials will hopefully educate on 
these topics as well. However, it appears that treating patients 
with ICIs irrespective of PD-L1 expression status may subject a 
larger number of likely non-responders to non-optimal therapy. 
At the same time, introducing a minimum PD-L1 expression 
requirement will ostensibly preclude a number of responders 
from receiving potentially efficacious ICI therapy, which becomes 
especially important in the second-line and platinum-refractory 
setting where there are few other efficacious treatments.
Additionally, the prognostic value of HPV status appears to hold 
up in patients treated with ICIs. In CheckMate 141, patients with 
p16-positive tumors experienced a numerically larger magnitude 
of benefit from nivolumab treatment as compared to patients 
with p16-negative tumors in terms of OS [HR (95% CI) = 0.56 
(0.32, 0.99) for patients with p16-positive tumors vs HR (95% 
CI) =  0.73 (0.42, 1.25) for patients with p16-negative tumors] 
(65). Subgroup analyses of response rates to pembrolizumab by 
HPV status revealed that the ORR in patients with HPV-positive 
disease was 22 vs 16% in patients with HPV-negative disease in 
the KEYNOTE-055 study, and 32 vs 14%, respectively, in the 
KEYNOTE-012 study (14, 45). However, neither the effects of 
tumor PD-L1 expression nor HPV status are sufficiently robust in 
guiding the use of ICI therapy at this time. The analysis of future 
randomized trials will be very important in that regard.
Another potential biomarker of response to ICIs is the 
interferon-γ (IFNγ) 6-gene signature [CXCL9 (C-X-C motif 
chemokine ligand 9), CXCL10 (C-X-C motif chemokine ligand 10), 
IDO1 (indoleamine 2,3-dioxygenase 1), IFNG (IFN-γ), HLA-DRA 
(major histocompatibility complex, class II, DR α), and STAT1 
(signal transducer and activator of transcription 1)] discussed by 
Chow et al. in the context of the KEYNOTE-012 study. In this 
analysis, a higher IFN-γ 6-gene score was significantly associated 
with response to pembrolizumab monotherapy and correlated 
with longer PFS and OS. The 6-gene score was not found to cor-
relate in any way with HPV status (87).
Overall, ways for better patient selection for ICI therapy con-
tinue to be the subject of ongoing investigations. Nevertheless, 
the survival benefits for the subset of patients with pretreated 
R/M SCCHN who achieve disease control on ICI monotherapy 
are impressive and a breakthrough in clinical practice.
A New CONTiNUUM OF CARe
Current clinical and observational evidence in the field supports 
the EXTREME regimen as standard of care for fit patients with 
R/M SCCHN in the first line, followed by the new treatment 
option of ICIs in second line (Figure 1). Maximizing the number 
of therapy lines and optimizing the order in which therapies are 
administered has historically been one of the most powerful 
tools for delivering maximum benefit to the greatest number of 
patients (17, 18). Until recently, this strategy has not been feasible 
in the treatment of R/M SCCHN; however, the emergence of ICIs 
has provided new options for an optimized continuum of care.
The majority of patients who do not respond during first-line 
treatments deteriorate rapidly; therefore, providing a continuum 
of care successfully requires maximizing the number of responses 
in first-line while patients are still relatively fit, thus allowing 
them to continue onto a second or third line of treatment. Indeed, 
responses are very important in patients with symptomatic 
disease, especially those with locoregional progression that can 
have devastating consequences. As the efficacy and safety of the 
EXTREME regimen are reproducible in observational studies, 
physicians’ decision-making when selecting and sequencing 
suitable therapies for patients with R/M SCCHN clearly pays off 
in clinical practice (57). Presently, there are no efficacy data for 
the reverse sequence (i.e., first-line ICIs followed by second-line 
utilization of the EXTREME regimen), or for robust follow-up 
therapeutic options for patients who progress on ICI treatment. 
Finally, platinum remains an important treatment component in 
SCCHN, and failure to treat with platinum-based CT in the first 
line could deprive patients of a line of therapy (5, 9, 52, 54, 73). 
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Notably, our proposed sequence of treatments circumvents these 
potential limitations. In summary, until data for ICI function in 
first-line R/M SCCHN are published, the treatment sequence of 
first-line EXTREME regimen followed by second-line ICIs is the 
only evidence-based approach, and thus off-label use of ICIs in 
the first-line treatment of fit patients should be discouraged for 
the time being.
There are also additional unknowns, stemming from the rela-
tive novelty of ICI therapy, that further complicate the therapy 
selection process. For example, although ICIs confer OS benefits 
as compared to the rest of the available second-, later-line, and 
platinum-refractory setting therapeutics, there is still a clear 
need for biomarkers of response in order to improve patient 
selection, boost ORRs, and prolong PFS time (13, 14, 65, 82). 
Other observations associated with ICI monotherapy, including 
accelerated tumor growth rate (hyperprogression) in up to 9% of 
patients with various tumor types (89) and low median PFS in 
R/M SCCHN (44, 45, 82), also suggest that this treatment option 
is not yet ready to be administered in the first-line setting without 
supporting data from prospective clinical trials. Indeed, the use of 
first-line ICIs outside of a clinical trial (i.e., non-evidence-based 
use) may subject patients to the risk of early progression with 
worsening symptomatology and performance status, and a lower 
likelihood of staying sufficiently fit to receive additional therapy. 
Therefore, as the EXTREME and similar regimens result in 80% 
disease control rates with a median PFS of ≥5 months, these treat-
ment options should continue to precede ICIs in the continuum 
of care for fit patients with R/M SCCHN.
CONCLUSiON
Treatment paradigms in R/M SCCHN are currently undergoing 
unprecedented evolution. Although the EXTREME regimen 
remains the evidence-based standard of care for first-line 
treatment of patients with R/M SCCHN, ICIs have shown 
promising OS results as monotherapies with tolerable toxicities 
and improvements in patient-reported outcomes in patients with 
R/M SCCHN in the second-, later-line, and platinum-refractory 
setting. Although the full extent of ICI functionality in different 
tumor types and therapy lines is still being discovered, we never-
theless anticipate that the pool of ICI-eligible patients will expand 
as data become available. The EXTREME regimen is supported by 
over 10 years of evidence, and its role in R/M SCCHN has been 
fully defined through years of clinical trials and observational 
studies. Given the impressive efficacy of ICIs in pretreated R/M 
SCCHN, the new challenge facing physicians is deciphering how 
to sequence available therapies optimally to maximally prolong 
patient survival, while maintaining the highest possible quality of 
life. Presently, the only evidence-based sequence places ICIs in the 
second-line and platinum-refractory settings, where they offer a 
promising alternative to historic therapeutic options. Therefore, 
fit patients with R/M SCCHN should continue to receive the 
EXTREME regimen in the first-line setting with cetuximab until 
PD. Quite excitingly, for the first time in a decade, physicians are 
able to offer patients with R/M SCCHN a continuum of care with 
efficacious therapy in multiple lines. Naturally, this treatment 
paradigm may evolve as additional data emerge.
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